MAP Kinase Pathways: Molecular Roads to Primary Acral Lentiginous Melanoma
Carregando...
Citações na Scopus
14
Tipo de produção
article
Data de publicação
2015
Editora
LIPPINCOTT WILLIAMS & WILKINS
Indexadores
Título da Revista
ISSN da Revista
Título do Volume
Autores
FERNANDES, Juliana D.
HSIEH, Ricardo
FREITAS, Luiz A. R. de
BRANDAO, Miguel A. R.
SANGUEZA, Martin
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
AMERICAN JOURNAL OF DERMATOPATHOLOGY, v.37, n.12, p.892-897, 2015
Resumo
The etiology and pathogenesis of lentiginous acral melanomas are poorly understood. Recent studies have postulated that DNA repair mechanisms and cell growth pathways are involved in the development of melanoma, particularly changes in the MAPK pathways (RAS, BRAF, MEK 1/2, and ERK 1/2). The aim of this study is to assess the status of the MAP kinase pathways in the pathogenesis of acral melanomas. The authors examined the components of the RAS-RAF-MEK-ERK cascades by immunohistochemistry in a series of 16 primary acral melanomas by tissue microarray. The expression of MAP kinase cascade proteins changed in most cases. The authors observed that 57.14% of cases were BRAF positive and that 61.53%, 71.42%, and 71.42% of cases were positive for MEK2, ERK1, and ERK2, respectively; RAS was not expressed in 92.31%, and all cases were negative for MEK1. The absence of RAS and positivity for MEK2, ERK1, and ERK2 were most seen in invasive cases with high thickness. These aspects of the MAPK pathway require further examination in acral melanomas between different populations. Nevertheless, the results highlight significant alterations in the MAP kinase cascades that are related to histological indicators of prognosis in primary acral melanomas.
Palavras-chave
melanoma, acral, skin cancer
Referências
- Bartkova J, 1996, CANCER RES, V56, P5475
- Goel VK, 2006, J INVEST DERMATOL, V126, P154, DOI 10.1038/sj.jid.5700026
- Weber A, 2003, LAB INVEST, V83, P1771, DOI 10.1097/01.LAB.0000101732.89463.29
- Spugnardi M, 2003, CANCER RES, V63, P1639
- Piliang MP, 2011, CLIN LAB MED, V31, P281, DOI 10.1016/j.cll.2011.03.005
- Venesio T, 2008, MODERN PATHOL, V21, P716, DOI 10.1038/modpathol.2008.41
- Bennett DC, 2003, ONCOGENE, V22, P3063, DOI 10.1038/sj.onc.1206446
- Scholl FA, 2009, CANCER RES, V69, P3772, DOI 10.1158/0008-5472.CAN-08-1963
- Sasaki Y, 2004, J INVEST DERMATOL, V123, P177, DOI 10.1111/j.0022-202X.2004.22722.x
- Reifenberger J, 2004, INT J CANCER, V109, P377, DOI 10.1002/ijc.11722
- Kuchelmeister C, 2000, BRIT J DERMATOL, V143, P275, DOI 10.1046/j.1365-2133.2000.03651.x
- Emery CM, 2009, P NATL ACAD SCI USA, V106, P20411, DOI 10.1073/pnas.0905833106
- Edlundh-Rose E, 2006, MELANOMA RES, V16, P471, DOI 10.1097/01.cmr.0000232300.22032.86
- Takata M, 2005, J INVEST DERMATOL, V125, P318, DOI 10.1111/j.0022-202X.2005.23812.x
- O'Leary JA, 2000, CLIN ORTHOP RELAT R, P206
- Schuierer MM, 2004, CANCER RES, V64, P5186, DOI 10.1158/0008-5472.CAN-03-3861
- Zebary A, 2013, J DERMATOL SCI, V72, P284, DOI 10.1016/j.jdermsci.2013.07.013
- Bello DM, 2013, ANN SURG ONCOL, V20, P3618, DOI 10.1245/s10434-013-3089-0
- Hsieh R, 2013, AM J DERMATOPATH, V35, P167, DOI 10.1097/DAD.0b013e31825fa1f6
- vanElsas A, 1996, AM J PATHOL, V149, P883
- Buery RR, 2011, ONCOL REP, V26, P783, DOI 10.3892/or.2011.1385
- Kong YY, 2010, ARCH PATHOL LAB MED, V134, P1740, DOI 10.1043/2009-0418-RAR.1
- Hong JW, 2014, ANN DERMATOL, V26, P195, DOI 10.5021/ad.2014.26.2.195
- Uribe P, 2006, J INVEST DERMATOL, V126, P161, DOI 10.1038/sj.jid.5700011
- Markovic SN, 2007, MAYO CLIN PROC, V82, P364
- Satyamoorthy K, 2003, CANCER RES, V63, P756
- Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092
- Greaves WO, 2013, J MOL DIAGN, V15, P220, DOI 10.1016/j.jmoldx.2012.10.002
- Jiveskog S, 1998, J INVEST DERMATOL, V111, P757, DOI 10.1046/j.1523-1747.1998.00376.x
- Tan KB, 2007, AM J SURG PATHOL, V31, P1902, DOI 10.1097/PAS.0b013e318073c600
- Tanami H, 2004, ONCOGENE, V23, P8796, DOI 10.1038/sj.onc.1208152
- Tsavachidou D, 2004, CANCER RES, V64, P5556, DOI 10.1158/0008-5472.CAN-04-1669
- Bradford PT, 2009, ARCH DERMATOL, V145, P427, DOI 10.1001/archdermatol.2008.609
- Bristow IR, 2008, J FOOT ANKLE RES, V1, DOI 10.1186/1757-1146-1-11
- SLINGLUFF CL, 1990, J SURG ONCOL, V45, P91, DOI 10.1002/jso.2930450207
- Bastian BC, 2000, CANCER RES, V60, P1968
- Jovanovic B, 2008, J INVEST DERMATOL, V128, P2696, DOI 10.1038/jid.2008.134
- Pollack LA, 2011, J AM ACAD DERMATOL, V65, pS78, DOI 10.1016/j.jaad.2011.05.030
- Jarell Abel D, 2007, Biologics, V1, P407
- Palmieri G, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-86
- Reed R., 1976, NEW CONCEPTS SURG PA
- Richmond-Sinclair NM, 2008, MELANOMA RES, V18, P336, DOI 10.1097/CMR.0b013e32830d8329
- Wu XC, 2011, J AM ACAD DERMATOL, V65, pS26, DOI 10.1016/j.jaad.2011.05.034